Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03414034 is registered in ClinicalTrials.gov with Cardiff Oncology as lead sponsor.

NCT NCT03414034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Cardiff Oncology
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2018
Completion date
October 16, 2023
Enrollment
72 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer